Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors - A CESAR study (Central European Society for Anticancer Drug Research - EWIV)
Journal article published in 2005 by
R.-D. Hofheinz,
C. Dittrich,
Jakupec 
,
A. Drescher,
U. Jaehde,
M. Gneist,
N. Graf V. Keyserlingk,
B. K. Keppler,
A. Hochhaus
,
A. Drescher,
U. Jaehde,
M. Gneist,
N. Graf V. Keyserlingk,
B. K. Keppler,
A. Hochhaus
